Supplementary Tables 1 and 2. A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma.
收藏数据链接：
官方服务：
资源简介：
Supplementary Table 1. Supplementary Table 2: PK Modeling Summary of WP1066 in Human Plasma
创建时间：
2022-05-16
